Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Oh I think I know why the jump occurred…but you probably won’t like the reason…imao..,r
Don't eat dinner b4 viewing what Hart got for RSU shrs this yr... https://www.sec.gov/Archives/edgar/data/704562/000168316824004762/xslF345X05/ownership.xml ...got little over 19k last yr...r
Hesitancy on new sales might be attributed to the Catalent model?...Would a startup commit a new drug/molecule/gene process to a company that might get bought out for sole manufacturing capacity?...I could imagine the pharma musical chairs scenario playing out at CTLT to make room for Ozempic....That horror show is probably on the minds of the startups looking for a home to get their drug going...imao...r
Viva Ecovadis…r
Markets are closed now...r
Not one question from any of the analyst over taking a "subjective" $100 mil charge? ...imao...r
Got ice for the bruising?… here come the option awards…r
From the 10k(bold text mine)...We utilize the liability method of accounting for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”). Under the liability method, deferred taxes are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. We provide a valuation allowance when it is more likely than not that our deferred tax assets will not be realized. On a periodic basis, we reassess the valuation allowance on our deferred tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In the fourth quarter of fiscal 2024, we reassessed the valuation allowance noting the shift of negative evidence outweighing positive evidence, due to our cumulative loss incurred over the three-year period ended April 30, 2024. This objective evidence also limited our ability to consider other subjective evidence such as projections for future growth. After assessing both the positive evidence and negative evidence, we determined it was more likely than not that our deferred tax assets would not be realized and therefore recorded a full valuation allowance related to federal and state deferred tax assets on April 30, 2024, resulting in income tax expense of $113.8 million (Note 8). ...r
They claimed a $113 million Income tax (benefit) expense in their consolidated statement ... https://www.sec.gov/ix?doc=/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm ...r
Well i think that report is a scam...maybe AI generated?...read further down:
The Non-Small Cell Lung Cancer Treatment (NSCLC) Market varies across regions due to differences in offshore exploration activities, regulatory frameworks, and investment climates.
North America
Presence of mature offshore oil and gas fields driving demand for subsea manifolds systems. ...r
Well if you were a hedge fund looking to short based on algos how would you do it?...r
My guess is that $7.28 trade yesterday aftermarket was a signal for today's action...imao...r
And there it is..."The report, which audited over 1,000 shareholder proposals from 2018-2022, found that 64% of the conservative-aligned proposals requested for No-Action were granted, while liberal-aligned proposals were granted No-Action relief by the SEC 52% of the time.
During that period, there were 1,063 shareholder proposals aligned with liberal interests, 101 categorized as neutral, 87 aligned with conservative interests, and two with unknown alignment submitted."
"When a shareholder submits a proposal to be included in a company's proxy materials for a vote at the company's annual general meeting or special meeting, the company may seek guidance from the SEC on whether it can exclude the proposal. The company typically provides reasons for exclusion based on SEC regulations, such as if the proposal falls under certain exempted categories or if it violates SEC rules.
Receiving a No-Action letter allows the company to exclude the shareholder proposal from its proxy materials without facing potential legal consequences from the SEC for doing so."
"Companies that received No-Action letters for left-wing investor proposals include Black Rock, Alphabet Inc., Amazon, AT&T, Best Buy, Autozone, Comcast, ExxonMobil, Johnson & Johnson, McDonald's and Pfizer."
"On Tuesday, BlackRock announced that it is partnering with a third proxy advisory firm to give its clients a wider range of investment counsel as critics suggested the mammoth asset manager is trying to make up for allegations that it leans into ESG (environmental, social, governance) tenets more than its fiduciary responsibilities merit."
"The National Center for Public Policy Research (NCPPR), a conservative think tank, plans to present proposals for a vote at each company, aimed at preventing the boards from making hyper-political decisions in the future, arguing that they have taken controversial positions at shareholders' expense."
Full article here... https://www.foxbusiness.com/politics/left-wing-activism-rampant-corporate-shareholder-proposal-process-report ... Fact...the #1 responsibility of corporate fiduciary governance and decision making is to strive to achieve a profit...currently this is being pushed to last on the list...imao...r
HALO news..."However, despite these positive financial indicators and recent developments, Piper Sandler opted to downgrade Halozyme's rating. The firm emphasized that while the recent updates are indeed beneficial, the current stock price already reflects these improvements. Moreover, Piper Sandler noted that substantial contributions from new products are not anticipated until 2025, prompting the downgrade to a Neutral rating. Following the downgrade by Piper Sandler, the market reaction was somewhat subdued, with Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock price experiencing a modest increase of 0.61%. Nevertheless, the stock closed at $51.16 on June 10, reflecting ongoing investor uncertainty regarding the company's future trajectory amidst the recent rating adjustment"....Wells Fargo and Wainwright maintaining recommendations tho?...AI involved?...r
What led to my previous post... https://www.msn.com/en-us/weather/topstories/string-of-earthquakes-rattles-southern-california-are-they-telling-us-something-bigger/ar-BB1nWAGD ...reprint from LA times...r
Just because...fault line map near Tustin... https://usgs.maps.arcgis.com/apps/webappviewer/index.html?id=5a6038b3a1684561a9b0aadf88412fcf ...type Tustin Ca in search box...r
When you look at HALO's 2023 10-k they show $115 mil in sales of bulk rHuPH20 product with the qualifier of "We expect product sales of bulk rHuPH20 and device partnered products to fluctuate in future periods based on the needs of our partners."...allow say a 25% markup and work backwards to what the market segment consist of if CDMO becomes a larger partner in the manufacture of the product....imao...r
And this... "A magnitude 2.6 earthquake struck Newport Beach on Wednesday afternoon, resulting in weak shaking in Orange County.
The epicenter of the quake, just southeast of Costa Mesa, was underneath Mariners Park. Weak shaking was felt in Irvine, Santa Ana, Huntington Beach, Garden Grove, Tustin, and Fountain Valley, according to people who reported the shaking to the U.S. Geological Survey's Did You Feel It? website."...r
Copy and paste the question in google for eternity...r
"Starting the following Friday, FTSE Russell releases updated but still preliminary index membership lists. Those updates are made on May 31, June 7, June 14 and June 21, all typically after 6 p.m. Finalization is June 28.
Meanwhile, on Monday, June 10, the reconstitution lock-down period begins. From that point, the rebalanced membership lists are considered final, pending any additional updates during the remainder of June."...r
Now that's a worthy offset for the note screwup...That's what worship at the Blackrock altar earns?...imao...r
Someone expecting new info to come out of the fireplace today?…I do know who should be standing in it tho…r
Russell rebalance on 5/24...r
Will Hart be MIA?…r
CC Monday after the bell…r
Re:Laughing Water...The mention of HALO in the article had me look at their 10k...on their comment regarding bulk rHuPH20..."future capital resource expeditures" ... "the costs of investments in our ENHANZE platform and auto-injector technology including development of new versions of rHuPH20 and auto-injector devices" ...and ... "the costs to develop and validate additional manufacturing processes of rHuPH20, auto-injectors, and testosterone replacement therapies"...with Catalent being excluded from these scenarios one would think that we would have the inside track for these considerations...no?...imao...r
No comment on the 200 contracts for $5 dec puts from Monday @ .85?…r
Agreed 👍…the sooner the better…imao…r
Interesting to note that last year when Ziebell, Hart, and Green were issued the RSU shrs they sold off anywhere from 40-50% of them on 4/11...this year none...wonder if the BOD had something to do with that (and the threat of lawsuits as well)...not that they deserve any at this point...imao...r
We will be looking at the Russell rebalancing soon...r
CTLT was providing the manufacturing component for Novo Nordisk on the injectible portion of their weight loss drug... CTLT just so happened to have the proverbial bucket at the foot of their bed when they hitched their wagon to Novo... Smart move by Novo now controlling the production and eliminating the potential problem of farming it out to a third party when you have a blockbuster drug like they do...imao...r
Got the hospital charge submitted for my wife’s biopsy for her lung mass(pet scan was indeterminate)…altogether $50k..wow…r
Plus the word "cross training" isn't in the their corporate vernacular...are the PD employees being utilized to maximize "tomorrow's" potential production flexibility requirements if a contract comes thru?...quits/LOA/promotions etc...at least try to window dress the yr report when the company is going to lose over $20 mil or more that measures are being taken to minimize the bleed and preparing for the turnaround without adding more labor costs than what is already incurred if PD revs continue to sag/remain neutral at best...imao...r
Does this require an amended S3 to be filed with a legal opinion by some entity?...r
Upon whose recommendation was K&L Gates brought on?…What is their exposure to legal recourse at this junction as well is a question that needs delving into… I was under the impression that we used them as supplemental legal and financial experts?… imao…r
This really needs to be said...If there's a lawsuit tailored to just clawbacks on all the execs and BOD members who on board as of the Note date and cashed in on any type of stock option (except Hancock and Carleone to a some degree- they were the only persons who made a buy on the open market) I would more than happy to sign on...sorry that some of them might not have anything to do with Note but the fact that they cashed in for a nice profit and failed to "put something back in appreciation of the opportunity to make some easy money" while the retail shareholder partially funded their gig...I do not have the smallest amount of sympathy if their lives are going to become hell now...I just don't...(my biggest desire is to see at least the 3 Amigo's who put their name on the Note paperwork and every quarterly statement since pay a price at a minimum)...imao...r
On the subject of hammers...don't they have clawbacks for removing cockeyed nails and ill-deserved performance stock option awards?...r
I'm assuming this is the hammer being provided to the lawsuit outfits... https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/704562/000168316824001433/avid_8k.htm ...r
If i'm reading this correctly OncXena's 2nd round of funding came from a venture fund Panacea Ventures in 2019 https://tracxn.com/d/companies/oncxerna/__kViAPtM8iAtZ6MvQALAA7HKvabipF79gRwoUzeR6ACA/funding-and-investors well they are out of the Cayman Islands ...close proximity to Mr Dart... https://www.sec.gov/Archives/edgar/data/1730485/000173048518000001/xslFormDX01/primary_doc.xml and OncXena is incorporated in the Caymans https://www.sec.gov/Archives/edgar/data/1914838/000156761922006334/xslFormDX01/primary_doc.xml ...r